194 related articles for article (PubMed ID: 20089093)
1. Is immediate postoperative intravesical chemotherapy beneficial in non-muscle- invasive bladder cancer?
Ayres BE; Crew JP;
BJU Int; 2010 Feb; 105 Suppl 2():14-7. PubMed ID: 20089093
[No Abstract] [Full Text] [Related]
2. Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done?
Soloway MS; Arianayagam M
Urology; 2010 Oct; 76(4):794-6. PubMed ID: 20932403
[No Abstract] [Full Text] [Related]
3. Re: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.
Stewart AB; Mostafid H
J Urol; 2005 Apr; 173(4):1433; author reply 1433. PubMed ID: 15758827
[No Abstract] [Full Text] [Related]
4. An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed?
Sylvester RJ; Oosterlinck W
Eur Urol; 2009 Jul; 56(1):43-5. PubMed ID: 19375216
[No Abstract] [Full Text] [Related]
5. Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?
Dobruch J; Herr H
BJU Int; 2009 Jul; 104(2):170-4. PubMed ID: 19493266
[No Abstract] [Full Text] [Related]
6. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
7. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
8. The place of intravesical chemotherapy as defined by results of prospective randomized studies (substances and treatment schemes).
Lamm DL; Griffith JG
Prog Clin Biol Res; 1992; 378():43-53. PubMed ID: 1301585
[No Abstract] [Full Text] [Related]
9. Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment?
Sylvester RJ
Eur Urol; 2007 Oct; 52(4):951-3; discussion 953-4. PubMed ID: 17374437
[No Abstract] [Full Text] [Related]
10. The use of intravesical chemotherapy and possibilities for improving its efficacy.
Sylvester RJ
Eur Urol; 2006 Aug; 50(2):233. PubMed ID: 18219714
[No Abstract] [Full Text] [Related]
11. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
12. Perioperative instillation therapy in superficial bladder cancer: is it effective regarding outcome and costs?
Engel RP; Witjes JA
Curr Opin Urol; 2009 Sep; 19(5):511-5. PubMed ID: 19553821
[TBL] [Abstract][Full Text] [Related]
13. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.
van der Meijden AP
Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591
[No Abstract] [Full Text] [Related]
14. Only an overall 15% net benefit emerges in favour of adjuvant intravesical chemotherapy when compared to transurethral resection alone for the prevention of recurrences of superficial bladder tumors.
Colombo R
Eur Urol; 2006 Aug; 50(2):233-4. PubMed ID: 18219715
[No Abstract] [Full Text] [Related]
15. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.
Parekh DJ; Bochner BH; Dalbagni G
J Clin Oncol; 2006 Dec; 24(35):5519-27. PubMed ID: 17158537
[TBL] [Abstract][Full Text] [Related]
16. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.
Lamm DL; Riggs DR; Traynelis CL; Nseyo UO
J Urol; 1995 May; 153(5):1444-50. PubMed ID: 7714962
[TBL] [Abstract][Full Text] [Related]
17. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
Huncharek M; Kupelnick B
Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
[TBL] [Abstract][Full Text] [Related]
18. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
[TBL] [Abstract][Full Text] [Related]
19. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; González Alvarez RC; Jalón Monzón A; Martínez Gómez FJ; Sánchez Trilla A; Regadera Sejas J
Arch Esp Urol; 2007; 60(1):36-43. PubMed ID: 17408170
[TBL] [Abstract][Full Text] [Related]
20. [Superficial bladder cancer: prophylaxis of recurrence and progression].
Miyanaga N; Akaza H; Koiso K
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2369-74. PubMed ID: 1719939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
